- Home
- PLSE
as of 12-15-2025 3:27pm EST
Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed-Field Ablation or nsPFA technology when used to ablate cellular tissue, can be used to treat a variety of medical conditions for which an optimal solution remains unfulfilled.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | HAYWARD |
| Market Cap: | 1.2B | IPO Year: | 2016 |
| Target Price: | $22.00 | AVG Volume (30 days): | 183.4K |
| Analyst Decision: | Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.13 | EPS Growth: | N/A |
| 52 Week Low/High: | $12.56 - $25.00 | Next Earning Date: | 11-05-2025 |
| Revenue: | $86,000 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | 1002.94% |
AI-Powered PLSE Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Pulse Biosciences Inc (DE) (PLSE)
Chief Commercial Officer
Avg Cost/Share
$18.53
Shares
4,600
Total Value
$85,238.00
Owned After
43,298
SEC Form 4
Chief Commercial Officer
Avg Cost/Share
$18.48
Shares
400
Total Value
$7,392.00
Owned After
43,298
SEC Form 4
Chief Commercial Officer
Avg Cost/Share
$18.49
Shares
20,000
Total Value
$369,800.00
Owned After
43,298
SEC Form 4
Chief Technology Officer
Avg Cost/Share
$16.21
Shares
20,000
Total Value
$324,200.00
Owned After
122,872
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Danahy Kevin Patrick | PLSE | Chief Commercial Officer | Oct 2, 2025 | Sell | $18.53 | 4,600 | $85,238.00 | 43,298 | |
| Danahy Kevin Patrick | PLSE | Chief Commercial Officer | Sep 19, 2025 | Sell | $18.48 | 400 | $7,392.00 | 43,298 | |
| Danahy Kevin Patrick | PLSE | Chief Commercial Officer | Sep 18, 2025 | Sell | $18.49 | 20,000 | $369,800.00 | 43,298 | |
| UECKER DARRIN | PLSE | Chief Technology Officer | Sep 17, 2025 | Sell | $16.21 | 20,000 | $324,200.00 | 122,872 |
Compare PLSE vs Leading Stocks
See how PLSE stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "PLSE Pulse Biosciences Inc (DE) - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.